|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN THE EFFECTIVE BENEFICIARIES OF THE SHARES Filed under Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||
|
Table II – Beneficial ownership derivative securities (for exampleputs, calls, warrants, options, convertible securities)
(for exampleputs, calls, warrants, options, convertible securities)
|
1. Title of derivative title |
2. Conversion or exercise price of the derivative security |
3. Transaction date (month/day/year) |
3A. Deemed execution date, if applicable (month/day/year) |
4. Transaction code |
5. Number of derivative securities acquired (A) or sold (D) |
6. Exercise date and expiry date |
7. Title and amount of the securities underlying the derivative securities |
8. Price of derivative securities |
9. Number of derivative securities beneficially owned as a result of reported transactions |
10. Form of ownership of derivative securities: direct (D) or indirect (I) |
11. Nature of Indirect Beneficial Ownership |
|
Coded |
V |
(A) |
(D) |
Exercise date |
Expiration date |
Title |
Amount or number of shares |
Reporting owners
| Name/address of declaring owner | Relationships | |||
|
Director |
10% Owner |
Officer |
Other |
|
|
WeismanWayne |
X |
Signatures
|
/s/ Jillian Dilmore, lawyer in fact |
2022-06-17 |
| **Signature of declaring person |
Date |
Explanation of answers:
|
If the form is completed by several declarants, see |
|
| Section 5(b)(v). |
(**) Intentional misrepresentation or omission of facts are federal criminal offenses. See |
| 18 USC 1001 and 15 USC 78ff(a). |
(1) |
Each Restricted Stock Unit (“RSU”) is the economic equivalent of one common share of Baudax Bio, Inc. (the “Company”), and may be settled, at the option of the Company, in cash, common stock or a combination of these. The RSUs will vest in full on June 15, 2023, subject to continuous service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the recipient to a cash payment equal to the “fair market value” (as defined in the Company’s 2019 Stock Incentive Plan) d one ordinary share of the company on the date of acquisition. . Note: Submit three copies of this form, one of which must be manually signed. If space is insufficient, See
Instruction 6 for the procedure. Potential individuals who need to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Disclaimer Baudax Bio Inc. published this content on June 17, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, onJune 17, 2022 8:12:03 PM UTC
.
|
|
|
|
|
|
Analyst recommendations on BAUDAX BIO, INC.
|
|
99.5%
|
||||
Baudax Bio, Inc. Technical Analysis Chart | MarketScreener
| Short term | Middle term | ||
| Long term | Tendencies | Bearish | Bearish |
Bearish
|
Please enable JavaScript in your browser settings to use dynamic graphics.  Sale |
|
| To buy | Medium consensus |
| TO BUY | Number of analysts |
| 1 | Last closing price |
| $0.76 | Average target price |
| $8.00 | Average Spread / Target |
Please enable JavaScript in your browser settings to use dynamic graphics.
Comments are closed.